Technical Analysis for SYN - Synthetic Biologics, Inc.

Grade Last Price % Change Price Change
grade C 0.5194 1.84% 0.01
SYN closed up 1.84 percent on Wednesday, February 19, 2020, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Feb 21
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical SYN trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Support Bullish 1.84%
1,2,3 Pullback Bullish Bullish Swing Setup 1.84%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.84%
Outside Day Range Expansion 1.84%
Down 3 Days in a Row Weakness 1.84%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Synthetics Biologics, Inc., a biotechnology company, focuses on the development of biologics for the prevention and treatment of serious infectious diseases. The company's product candidates include Trimesta, which is in Phase II clinical trial for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-004, which is in Phase II clinical trial for the treatment of clostridium difficile infection prevention; SYN-005, which is in preclinical stage for the treatment of pertussis; and SYN-001, which is in discovery stage for the treatment of acinetobacter infection. It has an agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and Japan, as well as with The University of Texas at Austin, Intrexon Corporation, and the Regents of the University of California. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetics Biologics, Inc. in February 2012. Synthetics Biologics, Inc. was founded in 2001 and is based in Rockville, Maryland.
Biotechnology Infectious Diseases Chemical Compounds Multiple Sclerosis Pyridines Fibromyalgia University Of California Carbamates Clostridioides Difficile Clostridium Difficile Infection Relapsing Remitting Multiple Sclerosis Cognitive Dysfunction Flupirtine Serious Infectious Diseases

Is SYN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.8499
52 Week Low 0.365
Average Volume 246,054
200-Day Moving Average 0.49
50-Day Moving Average 0.51
20-Day Moving Average 0.54
10-Day Moving Average 0.54
Average True Range 0.03
ADX 40.71
+DI 21.84
-DI 14.12
Chandelier Exit (Long, 3 ATRs ) 0.53
Chandelier Exit (Short, 3 ATRs ) 0.60
Upper Bollinger Band 0.58
Lower Bollinger Band 0.50
Percent B (%b) 0.26
BandWidth 15.63
MACD Line 0.00
MACD Signal Line 0.01
MACD Histogram -0.0068
Fundamentals Value
Market Cap 66.61 Million
Num Shares 128 Million
EPS -0.16
Price-to-Earnings (P/E) Ratio -3.17
Price-to-Sales 0.00
Price-to-Book 21.83
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.55
Resistance 3 (R3) 0.55 0.54 0.54
Resistance 2 (R2) 0.54 0.53 0.54 0.54
Resistance 1 (R1) 0.53 0.53 0.52 0.53 0.54
Pivot Point 0.52 0.52 0.52 0.52 0.52
Support 1 (S1) 0.51 0.51 0.50 0.51 0.50
Support 2 (S2) 0.50 0.51 0.50 0.50
Support 3 (S3) 0.49 0.50 0.49
Support 4 (S4) 0.49